Navigation Links
First Patient of NOTES Investigational Device Exemption (IDE) Study Successfully Treated With Ethicon Endo-Surgery Devices
Date:7/9/2009

CINCINNATI, July 9 /PRNewswire/ -- Ethicon Endo-Surgery, Inc. today announced the successful treatment of the first patient of its IDE feasibility trial. The case, which was performed at The Ohio State University Center for Minimally Invasive Surgery, marks the first natural orifice translumenal endoscopic surgery (NOTES) procedure involving the company's investigational devices. NOTES is a surgical method in which external incisions are eliminated, potentially leading to reduced pain, a quicker recovery and a faster return to normal activities for the patient.

The Ethicon Endo-Surgery Toolbox* for natural orifice surgery is a novel, comprehensive suite of devices specifically designed for this new approach to surgery. Several of these devices are featured in studies accepted for presentation this week at the 4th International NOSCAR Conference on NOTES in Boston. The patient treated at The Ohio State University Medical Center underwent a transgastric diagnostic peritoneoscopy with laparoscopic assistance prior to a laparoscopic gastric bypass procedure. The transgastric diagnostic peritoneoscopy is an exploratory surgery of the abdomen with the potential to treat adhesions, biopsy, etc.

"Using the Ethicon Endo-Surgery Toolbox, we were able to perform a thorough diagnostic peritoneoscopy in about the same timeframe as a typical laparoscopic procedure using the patient's mouth as the primary external access point. This protocol was designed to collect device data as well as intra-operative procedure data on the Ethicon Endo-Surgery Toolbox to assess the feasibility of using these devices within this procedural application," said Jeffrey Hazey, MD, FACS, assistant professor at the Ohio State University Center for Minimally Invasive Surgery. "I believe this study will serve as a critical step in advancing NOTES and NOTES specific technology, which holds great promise for improving surgery for both patients and physicians."

The study, which is the first to receive an investigational device exemption (IDE) to study devices for NOTES, will include up to 40 subjects undergoing either a diagnostic peritoneoscopy or cholecystectomy (gallbladder removal). Surgeons will use one of four different NOTES procedures supplemented with laparoscopic assistance. In addition to evaluating the feasibility of the Ethicon Endo-Surgery Toolbox for natural orifice surgery, the study is also designed to collect qualitative outcomes data and healthcare economic variables. The other three sites participating in the trial include Northwestern University Feinberg School of Medicine; University of California - San Diego Medical Center; and the University of Missouri University Hospital.

"The success of the first case of the IDE study and the associated data presentations at NOSCAR are important contributions in a growing body of evidence that demonstrates the promise of the Ethicon Endo-Surgery Toolbox for natural orifice surgery," said Kenneth Sumner, PhD, vice president, clinical and regulatory affairs, Ethicon Endo-Surgery. "We believe NOTES has enormous potential and Ethicon Endo-Surgery is committed to working with leading medical intuitions and societies, which we believe is essential to responsibly and effectively move natural orifice surgery forward."

About the Ethicon Endo-Surgery Toolbox for Natural Orifice Surgery*

The content of the investigational Ethicon Endo-Surgery Toolbox includes:

  • Tissue Apposition System
  • Steerable Flex Trocar with Rotary Access Needle
  • Flexible Bipolar Hemostasis Forceps
  • Flexible Maryland Dissector
  • Articulating Hook Knife
  • Articulating Snare
  • Articulating Needle Knife
  • Articulating Graspers
  • Articulating Biopsy Forceps

The devices listed above will be used within an IDE trial approved by the FDA, they are not currently cleared by FDA for commercial distribution.

About NOTES

NOTES is an investigational approach to minimally invasive surgery, in which external incisions are eliminated, potentially leading to reduced pain, a quicker recovery and a faster return to normal activities for the patient. In NOTES, surgery can be performed through a natural orifice, eliminating the need for an external incision. To assist with visualizing the internal surgical site, an endoscope is passed through a natural orifice such as the mouth or vagina and then through an internal incision in the stomach, bladder, colon or uterus.

About Ethicon Endo-Surgery

Ethicon Endo-Surgery, a Johnson & Johnson company, develops and markets advanced medical devices for minimally invasive and open surgical procedures, focusing on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as gastrointestinal health, gynecology and surgical oncology.

Ethicon Endo-Surgery is actively leading the development of NOTES through research to determine the most appropriate tools and technologies that may enable safe and effective NOTES surgery. The Ethicon Endo-Surgery NOTES Toolbox devices are investigational devices that have not been approved for marketing in the U.S. More information can be found at www.ethiconendo.com.

*Investigational devices limited by federal law to investigational use only in the U.S.


'/>"/>
SOURCE Ethicon Endo-Surgery, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president of ... In his new role, Marziani will lead the company,s business development and sales team, ... outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... England , May 24, 2016 ... and Education in Clinical Neurophysiology  Elsevier ... information products and services, today announced the launch of ... an open access journal that focuses on clinical practice ... research, case reports, clinical series, normal values and didactic ...
(Date:5/23/2016)... 2016 Global Paclitaxel Market 2016 ... 12 companies and the Paclitaxel analysis in this study ... industry and its players. This is the ... details the current state of the industry while providing ... applications and industry chain structure. The Paclitaxel market analysis ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... , ... Loma Linda University Health (LLUH) has officially broken ground on the ... 3,000 people looked on as the shovels hit the dirt at the community groundbreaking ... During the program, Richard H. Hart, MD, DrPH, president, LLUH, recapped the history of ...
(Date:5/24/2016)... PA (PRWEB) , ... May 24, 2016 , ... A ... will rely heavily on their access to trusted resources, both in face-to-face interactions and ... Young Men of Color,” researchers concluded that the creative use of mobile digital devices ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is co-founder, ... in the development of technological innovations that lead to broad-based healthcare solutions. , ...
(Date:5/24/2016)... ... 2016 , ... As reported by MassGeneral.org, on May 8 – 9, 2016, ... States . The 64-year-old patient who received the transplant had undergone a partial penectomy ... a natural appearance, but also urinary and sexual function for the patient who has ...
(Date:5/24/2016)... ... May 24, 2016 , ... Local ... Republic on September 21, 2016. Dr. Gerard, who holds a Doctorate of Chiropractic ... not-for-profit organization promoting health and wellness in Third World countries where resources are ...
Breaking Medicine News(10 mins):